Abstract:Development of new effective EGFR-targeted antitumor agents is needed because of their clinical significance. A new series of imidazolone-sulphonamide-pyrimidine hybrids was designed and synthesized as modified analogs of some reported EGFR inhibitors. The cytotoxic activity of all the synthesized hybrids was investigated against the breast MCF-7 cancerous cell line using doxorubicin (Dox) as a positive control. 4-(Furan-2-ylmethylene)imidazolone-sulphonamide-pyrimidine 6b had the best potent activity against MCF-7 cells with IC 50 result of 1.05 μM, which was better than Dox (IC 50 = 1.91 μM). In addition, mechanistic studies revealed the ability of compounds 5g , 5h and 6b to inhibit EGFR kinase. Cell cycle analysis revealed that compound 6b can halt MCF-7 cells at the G1 phase with a concomitant decrease in cellular percentage at the S and G2/M phases. This compound produced a noticeable rise in the proportion of apoptotic cells with regard to the untreated control. Furthermore, the effects of hybrid 6b on the expression levels of pro-apoptotic Bax and pro-survival Bcl2 were assessed. The results showed that this compound upregulated the level of Bax expression as well as declined the expression value of Bcl-2 with regard to the untreated control.

What problem does this paper attempt to address?

This paper mainly discusses the design, synthesis, and biological activity of a novel imidazolone-sulfonamide-pyrimidine hybrid molecule as a potential epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor and apoptosis inducer. Researchers designed and synthesized a series of 4-(arylalkyl)imidazolone-sulfonamide-pyrimidine compounds, which were structurally modified based on reported EGFR inhibitors. In vitro experiments demonstrated significant cytotoxicity of these compounds against breast cancer MCF-7 cell line, compared to docetaxel. Among all the synthesized compounds, 4-(furan-2-ylmethyl)imidazolone-sulfonamide-pyrimidine 6b exhibited the strongest activity with an IC50 value of 1.05 mM, superior to docetaxel with an IC50 value of 1.91 mM. Furthermore, 6b showed good EGFR inhibition activity with an IC50 value of 0.09 mM, close to the inhibitory effect of the standard drug lapatinib. Cell cycle analysis revealed that 6b could arrest the MCF-7 cells in the G1 phase and promote apoptosis. Further experiments demonstrated that 6b induced cell apoptosis by downregulating the expression of anti-apoptotic protein Bcl-2 and upregulating the expression of pro-apoptotic protein Bax. In summary, the paper aims to develop more effective EGFR-targeting anti-tumor drugs and identifies 6b as a promising candidate drug through synthesis and biological activity evaluation. It may inhibit tumor growth by regulating the cell cycle and inducing apoptosis.

Synthesis and biological research of new imidazolone-sulphonamide-pyrimidine hybrids as potential EGFR-TK inhibitors and apoptosis-inducing agents